SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending following a strategic deal to repurchase a significant stake in its Ireland Fab 34 facility, a move that investors view as a major vote of confidence in the company's manufacturing turnaround and future AI chip demand. The community is actively debating the stock's potential for a broader recovery, with many traders closely monitoring price levels to see if the recent momentum can sustain a breakout above key resistance zones.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is maintaining strong momentum as the community rallies around its unique 'culture-first' brand identity ahead of key industry events. Investors are actively discussing its long-term potential, citing consistent organic growth and a commitment to advocacy that resonates with supporters beyond traditional market metrics.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is trending following a strategic partnership with Ukraine's Spetstechnoexport to advance multi-domain uncrewed systems and the acquisition of Apium Swarm Robotics, fueling community excitement around the company's expanding defense capabilities. Investors are actively debating the stock's potential as a key player in the drone sector, balancing enthusiasm for new NATO and defense contracts against concerns over share dilution and the need for more concrete revenue guidance.

Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

Soleno Therapeutics Inc

Soleno Therapeutics is surging following the FDA approval of VYKAT XR, the first treatment for hyperphagia in Prader-Willi syndrome, fueling community discussion around its blockbuster potential and possible future acquisition. Investors are closely monitoring the stock's transition from a clinical-stage development play to a commercial-stage entity, with analysts aggressively revising price targets upward to reflect the de-risked profile.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending as traders closely watch the stock's relative strength and consolidation patterns amid a broader market pullback. Market participants are actively discussing the impact of recent subscription price increases on revenue growth while monitoring key technical resistance levels that could trigger a potential breakout.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is currently experiencing intense volatility and downward pressure as investors grow increasingly frustrated with leadership's communication and the lack of a major partnership or buyout announcement. The community is actively debating the impact of recent R&D leadership changes and speculative proxy pressure, while many remain focused on the potential value of the Matrix-M platform to spark a significant recovery.

“Buttcoin - The Next Bitcoin” is the memecoin version of Bitcoin. Launched on January 30, 2025, on Pump.fun, it’s a community-owned memecoin on Solana. The idea was inspired by a 4:20 minutes long YouTube video from 2013 called "The Next Bitcoin?" by James D. McMurray.

The Next Bitcoin

Investors are rallying behind $BUTTCOIN as a satirical movement aimed at disrupting the traditional financial system, with community members actively promoting it as the next major meme cycle. The conversation is driven by intense speculation and viral narratives, with supporters urging others to join the movement to flip Bitcoin while others emphasize the coin's role as a lighthearted commentary on market volatility.

ProShares Trust - ProShares K-1 Free Crude Oil ETF

ProShares K-1 Free Crude Oil Strategy ETF

ProShares K-1 Free Crude Oil Strategy ETF is attracting attention as the broader energy sector faces significant volatility driven by a growing global crude supply glut and shifting geopolitical dynamics, including potential ceasefire developments and diplomatic negotiations. Market participants are actively debating the sustainability of current oil price levels, with many community members focusing on technical indicators, inventory data, and the potential impact of geopolitical cooling on long-standing supply-shock narratives.

Satellogic, Inc. operates as a vertically integrated geospatial company. It is creating and continuously enhancing the first scalable, fully automated EO platform with the ability to remap the entire planet at both high-frequency and high-resolution, providing accessible and affordable solutions for customers. The company was founded by Emiliano Kargieman and Gerardo Richarte in July 2010 and is headquartered in Davidson, NC.

Satellogic Inc - Ordinary Shares - Class A

Satellogic is currently generating significant investor interest as it rides the momentum of the booming space sector, fueled by anticipation of a potential SpaceX IPO and increased demand for defense-related geospatial intelligence. The community is actively discussing the stock's long-term growth potential and recent technical price action, while monitoring key catalysts like upcoming industry symposiums, government contract developments, and the company's recent expansion of its satellite constellations.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is seeing increased investor attention as a leading example of post-quantum cryptography in a recent Google research paper, bolstering the community's long-term thesis on its security standards. While some users are actively debating potential institutional utility and the impact of the foundation's shift to the U.S., community discussions remain heavily polarized between long-term proponents betting on technical robustness and critics focused on recent price trends.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Anavex Life Sciences' (AVXL) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital reissued a "buy" rating and issued a $24.00 price target on shares of Anavex Life Sciences in a research note on Tuesday...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...

Anavex Life Sciences Stock Crushed As European Alzheimer's Drug Filing Pulled After EMA Pushback

Anavex shares fall after pulling EU filing for blarcamesine in Alzheimer's; EMA feedback prompts more data work.read more...

<ul class="summary-bullets"><li>Anavex stated it withdrew the application for blarcamesine after the EMA’s Committee for Medicinal Products for Human Use indicated that it would not issue a positive opinion for the company’s Alzheimer’s drug at this time.</li><li>The company added that it filed the blarcamesine application following guidance from the EMA’s small and medium-sized enterprises office to move forward with marketing authorization preparations.</li><li>This comes two days after Anavex reported new data about blarcamesine, suggesting a slowdown in brain shrinkage.</li></ul>Anavex Life Sciences Corp. (AVXL) shares tanked more than 33% in Wednesday’s opening trade after the company announced that it has withdrawn its marketing authorization application for its Alzheimer’s drug, blarcamesine, in the European Union.Anavex stated that the decision to withdraw the application follows feedback from the European Medicines Agency’s Committee for Medicinal Products for Human Use.This comes two days after Anavex&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/avxl-stock-soars-anavex-alzheimers-drug-blarcamesine-slows-brain-shrinkage/cZ3mhyrRI0F">reported</a> new data about blarcamesine, suggesting a slowdown in brain shrinkage.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/AVXL">Anavex Life Sciences</a> trended in the ‘extremely bullish’ territory at the time of writing.<h2 class="st-heading-2">Why Did Anavex Withdraw Application?</h2>Anavex stated that it withdrew the application for blarcamesine after the EMA’s Committee for Medicinal Products for Human Use indicated that it would not issue a positive opinion for the company’s Alzheimer’s drug at this time.The company added that it filed the blarcamesine application following guidance from the EMA’s small and medium-sized enterprises (SMEs) office to move forward with marketing authorization preparations.“Anavex now has to take note of the differing assessment of the CHMP at the EMA and will consider the constructive feedback received from the CHMP and focus on gathering additional data and conducting further analyses to address the points raised by the CHMP,” the company stated.<h2 class="st-heading-2">New Blarcamesine Trial Data Suggests Slowdown In Brain Shrinkage</h2>Earlier this week, Anavex reported new data about blarcamesine, suggesting a slowdown in brain shrinkage. Brain shrinkage is a key marker of Alzheimer’s progression.At the AD/PD 2026 Conference, Anavex presented new data on blarcamesine from its Phase IIb and Phase III programs, indicating that preservation of brain volume is associated with improved patient outcomes.The company said its trial data suggest patients with wild-type SIGMAR1 and COL24A1 genes may see greater clinical and structural benefits from blarcamesine.MRI biomarker analysis showed a strong and consistent link between reduced brain atrophy and improvements in cognition, daily activities, and overall clinical outcomes, Anavex said.<a href="https://stocktwits.com/symbol/AVXL">AVXL stock</a> is down 21% year-to-date and 71% over the past 12 months. The SPDR S&amp;P Biotech ETF (XBI) is up 43% over the past 12 months, while the iShares Biotechnology ETF (IBB) is up 25%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lmt-stock-lockheed-martin-quadruple-precision-strike-missiles-production-iran-war/cZ3YFRyRIS9">Lockheed Martin To Quadruple Precision Strike Missile Output After First Combat Use In Iran War</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, an Anavex Life Sciences Corp. logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

AVXL Stock Tanks After Anavex Withdraws EU Bid For Alzheimer's Drug

Anavex stated that the decision to withdraw the application follows feedback from the European Medicines Agency’s Committee for Medicinal Products for Human Use.

Equity

<ul class="summary-bullets"><li>The company said that its trial data also show that patients with wild-type SIGMAR1 and COL24A1 genes may experience substantially greater clinical and structural benefit from blarcamesine.</li><li>An analysis of MRI biomarkers showed a strong and consistent correlation between reduced brain atrophy and improvements across primary and secondary clinical endpoints, Anavex said.</li><li>This includes cognition, activities of daily life, and global clinical cognitive and functional outcome.</li></ul>Anavex Life Sciences Corp. (AVXL) on Monday reported new data about its Alzheimer’s drug blarcamesine, suggesting a slowdown in brain shrinkage.At the AD/PD 2026 Conference, Anavex presented new data on blarcamesine from its Phase IIb and Phase III program, indicating that preservation of brain volume is linked to improved patient outcomes. The drug remains investigational and has not been approved by regulators.<a href="https://stocktwits.com/symbol/AVXL">Anavex shares</a> were up more than 13% in Monday’s opening trade.<h2 class="st-heading-2">What Does The Data Show?</h2>Anavex stated that the new data points to a reduction in brain volume loss over time. Brain shrinkage is a key marker of Alzheimer’s progression.“The patient-friendly oral administration, the manageable side effects, and the clinical efficacy—particularly in the genetically defined ABCLEAR3 population—make blarcamesine, in conjunction with the associated biomarker signal, a promising drug candidate for patients with early-stage Alzheimer’s disease,” said Timo Grimmer, member of the Anavex Scientific Advisory Board.The company said that its trial data also shows that patients with wild-type SIGMAR1 and COL24A1 genes may experience substantially greater clinical and structural benefit from blarcamesine.An analysis of MRI biomarkers showed a strong and consistent correlation between reduced brain atrophy and improvements across primary and secondary clinical endpoints, including cognition, activities of daily life, and global clinical cognitive and functional outcome.“The consistent relation between structural preservation of brain volume and functional outcomes further drives our dedication to developing a novel disease-modifying Alzheimer’s treatment with our oral blarcamesine,” said Anavex CEO Christopher U. Missling.<h2 class="st-heading-2">What Does Anavex Do?</h2>Anavex is a New York-based biopharmaceutical that is involved in the development of therapeutics for the treatment of various disorders, including Alzheimer’s disease, Parkinson’s disease, and schizophrenia, among others.The company’s preclinical studies of blarcamesine showed that the oral drug candidate has the potential to halt or reverse the course of Alzheimer’s disease.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits around the company trended in the ‘extremely bullish’ territory, with message volumes at ‘high’ levels at the time of writing.One bullish user said that Anavex’s brain volume preservation data is “incredibly exciting.”<stembedurl>https://stocktwits.com/Logic102/message/648270407</stembedurl><a href="https://stocktwits.com/symbol/AVXL">AVXL stock</a> is up 26% year-to-date, but down 54% over the past 12 months. The SPDR S&amp;P Biotech ETF (XBI) is up 41% over the past 12 months, while the iShares Biotechnology ETF (IBB) is up 23%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/gold-price-recovers-as-trump-postpones-attack-on-iran-5-days-down-16-month/cZ3ma5TRI0O">Gold Price Recovers To $4,450 On Trump’s Iran Attack Pause – But Yellow Metal Is Still Down 15% In A Month After ‘Sell Everything’ Rout</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

AVXL Stock Soars After Anavex’s New Data Suggests Its Alzheimer’s Drug May Slow Brain Shrinkage

Anavex presented new data from its Phase IIb and Phase III blarcamesine programs, showing that preservation of brain volume is associated with improved patient outcomes.

D. Boral Capital Reiterates Buy Rating for Anavex Life Sciences (NASDAQ:AVXL)

D. Boral Capital reaffirmed a "buy" rating and issued a $24.00 price objective on shares of Anavex Life Sciences in a report on Monday...

Is AC Immune (ACIU) Outperforming Other Medical Stocks This Year?

Here is how AC Immune (ACIU) and Anavex Life Sciences (AVXL) have performed compared to their sector so far this year.

Anavex Life Sciences (NASDAQ:AVXL) Stock Price Crosses Above 50 Day Moving Average - Time to Sell?

Anavex Life Sciences (NASDAQ:AVXL) Shares Cross Above 50 Day Moving Average - Time to Sell...

Anavex Life Sciences (NASDAQ:AVXL) Stock Price Passes Above Fifty Day Moving Average - What's Next?

Anavex Life Sciences (NASDAQ:AVXL) Shares Cross Above 50-Day Moving Average - Should You Sell...

What's Going On With Anavex Life Sciences Stock On Wednesday?

Anavex Life Sciences' stock rises despite no news, up over 40% this year as investors watch Alzheimer's program updates and analyst targets.read more...

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Anavex Life Sciences Corporation

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.07	--	--	N/A
Q1 '26	-$0.12	-$0.06	51.35%	BEAT
Q4 '25	-$0.15	-$0.11	26.67%	BEAT
Q3 '25	-$0.14	-$0.16	-12.41%	MISSED
Q2 '25	-$0.15	-$0.13	13.33%	BEAT

AVXL
Anavex Life Sciences Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q2 '26

Historical Earnings

Latest AVXL News

AVXLAnavex Life Sciences Corp